In India, cancer treatment often follows a standardised approach, bucketing the treatments based on the stage and type of cancer. However, the West adopts a rather nuanced strategy with genome research to understand the exact type of cancer within a certain stage and type and administer targeted therapy, thereby hitting a higher recovery rate.
Hitesh Goswami and Kshitij Rishi founded the Bengaluru-based oncology precision startup 4baseCare in 2018 to introduce a similar approach to treating oncology patients in India. Recently, Infosys Innovation Fund invested close to $1 million in the leading precision oncology firm. They were also the past winners of the Karnataka government’s ‘Elevate’ initiative that supports innovative early-stage startups.
A few months ago, deep tech-focused venture fund Yali Capital led a Series A funding round and raised $6 million.
Genome Technology for Targeted Care
In an exclusive interaction with AIM, co-founder and CEO of 4baseCare, Goswami, explained the methodology behind cancer treatment. Previously, cancer treatment was uniform. All patients received the same therapy based on the cancer type and stage, and individual differences were not considered in treatment plans.
Goswami said that today, lung cancer stage-2 and stage-3 patients are subgrouped into 12 to 15 categories; each requiring distinct treatments as therapies effective for one group may not work for another and could even cause adverse reactions.
According to him, sequencing one human genome took around 15 years and $3.2 billion. Now that the Human Genome Project has concluded, Goswami believes the procedure can be done at a cost of $100 for a genome in a couple of years.
Notably, genome testing for oncology has grown rapidly in India. What stood at 5,000-6,000 tests in a year in 2019 has now touched 2 lakh. Goswami estimates that the market will easily hit 3 lakh tests.
Source: analyticsindiamag
#healthcarestartup #startupfunding #dseide
Hitesh Goswami and Kshitij Rishi founded the Bengaluru-based oncology precision startup 4baseCare in 2018 to introduce a similar approach to treating oncology patients in India. Recently, Infosys Innovation Fund invested close to $1 million in the leading precision oncology firm. They were also the past winners of the Karnataka government’s ‘Elevate’ initiative that supports innovative early-stage startups.
A few months ago, deep tech-focused venture fund Yali Capital led a Series A funding round and raised $6 million.
Genome Technology for Targeted Care
In an exclusive interaction with AIM, co-founder and CEO of 4baseCare, Goswami, explained the methodology behind cancer treatment. Previously, cancer treatment was uniform. All patients received the same therapy based on the cancer type and stage, and individual differences were not considered in treatment plans.
Goswami said that today, lung cancer stage-2 and stage-3 patients are subgrouped into 12 to 15 categories; each requiring distinct treatments as therapies effective for one group may not work for another and could even cause adverse reactions.
According to him, sequencing one human genome took around 15 years and $3.2 billion. Now that the Human Genome Project has concluded, Goswami believes the procedure can be done at a cost of $100 for a genome in a couple of years.
Notably, genome testing for oncology has grown rapidly in India. What stood at 5,000-6,000 tests in a year in 2019 has now touched 2 lakh. Goswami estimates that the market will easily hit 3 lakh tests.
Source: analyticsindiamag
#healthcarestartup #startupfunding #dseide
In India, cancer treatment often follows a standardised approach, bucketing the treatments based on the stage and type of cancer. However, the West adopts a rather nuanced strategy with genome research to understand the exact type of cancer within a certain stage and type and administer targeted therapy, thereby hitting a higher recovery rate.
Hitesh Goswami and Kshitij Rishi founded the Bengaluru-based oncology precision startup 4baseCare in 2018 to introduce a similar approach to treating oncology patients in India. Recently, Infosys Innovation Fund invested close to $1 million in the leading precision oncology firm. They were also the past winners of the Karnataka government’s ‘Elevate’ initiative that supports innovative early-stage startups.
A few months ago, deep tech-focused venture fund Yali Capital led a Series A funding round and raised $6 million.
Genome Technology for Targeted Care
In an exclusive interaction with AIM, co-founder and CEO of 4baseCare, Goswami, explained the methodology behind cancer treatment. Previously, cancer treatment was uniform. All patients received the same therapy based on the cancer type and stage, and individual differences were not considered in treatment plans.
Goswami said that today, lung cancer stage-2 and stage-3 patients are subgrouped into 12 to 15 categories; each requiring distinct treatments as therapies effective for one group may not work for another and could even cause adverse reactions.
According to him, sequencing one human genome took around 15 years and $3.2 billion. Now that the Human Genome Project has concluded, Goswami believes the procedure can be done at a cost of $100 for a genome in a couple of years.
Notably, genome testing for oncology has grown rapidly in India. What stood at 5,000-6,000 tests in a year in 2019 has now touched 2 lakh. Goswami estimates that the market will easily hit 3 lakh tests.
Source: analyticsindiamag
#healthcarestartup #startupfunding #dseide
